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Dialysis patients display a high cardiovascular mortality, the causes of which are still not completely
explained, but are related to uremic toxicity. Among uremic toxins, homocysteine and cysteine are both
substrates of cystathionine b-synthase and cystathionine g-lyase in hydrogen sulﬁde biosynthesis,
leading to the formation of two sulfur metabolites, lanthionine and homolanthionine, considered stable
indirect biomarkers of its production. Hydrogen sulﬁde is involved in the modulation of multiple
pathophysiological responses. In uremia, we have demonstrated low plasma total hydrogen sulﬁde
levels, due to reduced cystathionine g-lyase expression.
Plasma hydrogen sulﬁde levels were measured in hemodialysis patients and healthy controls with
three different techniques in comparison, allowing to discern the different pools of this gas. The protein-
bound (the one thought to be the most active) and acid-labile forms are signiﬁcantly decreased, while
homolanthionine, but especially lanthionine, accumulate in the blood of uremic patients. The hemodi-
alysis regimen plays a role in determining sulfur compounds levels, and lanthionine is partially removed
by a single dialysis session. Lanthionine inhibits hydrogen sulﬁde production in cell cultures under
conditions comparable to in vivo ones. We therefore propose that lanthionine is a novel uremic toxin. The
possible role of high lanthionine as a contributor to the genesis of hyperhomocysteinemia in uremia is
discussed.
© 2016 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights
reserved.1. Introduction
Chronic kidney disease (CKD) is characterized by a high car-
diovascular (CV) mortality, which cannot be entirely explained by
the increase in traditional CV risk factors. Among the numerous
uremic toxins/biomarkers, retained in all stages, but more mark-
edly in uremia, affecting the vasculature, sulfur-containing me-
tabolites participating in the methionine-homocysteine cycle and
the transsulfuration pathway, such as cysteine (Cys), and homo-
cysteine (Hcy), are increased. Pertaining to these pathways is also
hydrogen sulﬁde (H2S), the third gasotransmitter after nitric oxideerna).
de Biochimie et Biologie Moléculand carbon monoxide, which exerts several beneﬁcial biological
functions (anti-oxidative and anti-inﬂammatory effects, lifespan
extension, regulation of vascular tone and blood pressure-lowering,
protection from ischemia-reperfusion injury, etc.) [1]. Low plasma
H2S levels have been detected in uremia [2,3], which is linked to a
downregulation of cystathionine-ɣ-lyase (CSE), one of themain H2S
forming enzymes [4e7].
Cys and Hcy are utilized as substrates for H2S biosynthesis by the
enzymes cystathionine- b-synthase (CBS), the above-mentioned
CSE, and 3-mercaptopiruvate sulfurtransferase (MPST). Two novel
sulfur metabolites, lanthionine and homolanthionine, have been
found to be possible by-products of H2S production (Fig. 1) [8,9].
Condensation of two molecules of Cys (b-replacement reaction)
produces H2S and lanthionine, while condensation of two mole-
cules of Hcy produces H2S and homolanthionine (g-replacementaire (SFBBM). All rights reserved.
Fig. 1. Lanthionine and homolanthionine formation. Lanthionine is formed from condensation of two Cys molecules (panel A). Homolanthionine is formed from condensation of
two Hcy molecules (panel B). Both reactions can be carried out by either CBS or CSE independently, under physiological conditions.
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products of H2S metabolism and indirect biomarkers of its pro-
duction [8,9].
Accuracy and precision of H2S detection in biological samples
may be signiﬁcantly affected by the various methodologies
employed, which provide somewhat divergent results [10,11]. In
fact, H2S is present in different pools, which mediate various H2S
biological effects. Aim of our work was to establish whether the
most important H2S-related sulfur compounds displayed speciﬁc
alterations, which could be the distinct signature of kidney failure.
Furthermore, we intended to approach the possible mechanism(s)
which, through unbalanced metabolism and/or deranged emunc-
tory, may affect sulfur compounds levels, particularly those per-
taining to increased CV risk in CKD. In our work, we tested three
different methods (chromatographic with monobromobimane
derivatization, potentiometric, utilizing a micro-electrode, and
spectrophotometric with methylene blue) for plasma H2S mea-
surement in a control group and a group of hemodialysis patients,
thus being able to compare results from all currently used methods
and discern among the various H2S forms in circulation. We also
measured lanthionine and homolanthionine, as well as Hcy, Cys
and other relevant compounds, in uremia compared to controls,
and studied the effect of different hemodialysis modalities and
those of a single dialysis session. In addition, the effects of lan-
thionine on H2S release were also tested in cell cultures.
2. Materials and methods
2.1. Patients and study design
A control group of 22 healthy subjects recruited among hospital
staff (mean age ¼ 53 y, age range 32e59 y) and 67 uremic subjects
(mean age ¼ 63 y, age range 45e72 y) on chronic hemodialysis
were recruited, provided that they were in stable clinical condi-
tions, treated with dialysis since at least 6 months, Kt/V > 1.4, and
not affected by systemic diseases such as lupus erythematosus,
diabetes mellitus, cancer, or evidence of other systemic diseases
antecedent to renal failure, which would be confounding variables.
Patients were also hepatitis C virus antibody negative. Previoustransplant patients were excluded. Patients were treated with
erythropoietin and other drugs commonly utilized in this popula-
tion for anemia, hypertension and secondary hyperparathyroidism,
following KDOQI guidelines.
Patients were either on standard low-ﬂux HD, with dialysis
membrane polysulfone (n ¼ 37, Fresenius Medical Care, Bad
Homburg, Germany), or low-ﬂux HD, with dialysis membrane
polyethersulfone (n ¼ 12, Nordic Medcom AB, Borås, Sweden), or
HDF (n ¼ 12), membrane high-ﬂux steam-sterilized polysulfone, or
PHF, with high-ﬂux polyethersulfone (n ¼ 6).
The group of uremic patients on standard low-ﬂux HD with
polyethersulfone or high-ﬂux PHF was utilized also for studying
H2S behavior during dialysis (pre-post measurements and time-
course), and sulfur compounds determinations.
All patients gave their informed consent. Procedures followed
were in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as revised in 1983. The
study was approved by our institutions' ethics committee (protocol
number 374/2007 of the Second University of Naples).
Blood was drawn, in the fasting state, by venipuncture. In pa-
tients, blood was obtained before the session, or before and after
the session, or at various times during the same session, as
mentioned in the relevant experiments. Blood samples were drawn
in plastic tubes, and plasma or serum were immediately obtained
through brief (50) centrifugation at 3000  g. Plasma or serum
samples were aliquoted and stored at 20 C before analysis.
2.2. H2S detection with high performance liquid chromatography
(HPLC) monobromobimane (MBB) method
Plasma was drawn utilizing lithium-heparin Vacutainers (BD
Diagnostics 368884, Italy). Three different protocols were utilized
in order to liberate and detect free H2S, acid-labile sulﬁde, and
bound sulfane sulfur (which are the major sulﬁde pools, important
in regulating the amount of bioavailable sulfur) according to the
general principle of Shen's method [10], with modiﬁcations
regarding one crucial step, as indicated below, in order to keep
sample manipulation at a minimum. An Agilent 1100 series high
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XTerra 18RP (5 mm, 80 Å, 4.6  250 mm) column (Phenomenex srl,
Casalecchio di Reno, Italy), a ﬂuorescence detector, and a gradient
employing two mobile phases at 0.600 mL/min: (A) water 0.1% TFA
(triﬂuoroacetic acid) (v/v); (B) CH3CN 99.9%, 0.1% TFA (v/v).
Free H2S. In an hypoxic chamber, under nitrogen ﬂux, 30 mL of
plasmawere mixed with 70 mL of reaction buffer (Tris-HCl 100 mM,
pH 9.5, 0.1 mM Diethylenetriaminepentaacetic acid, DTPA), to
release all H2S present in samples and to stabilize H2S in its HS
form, and 50 mL of 10 mM MBB solution in CH3CN. This mixture is
incubated for 30 min in a hypoxic chamber at room temperature.
After incubation, 50 mL of sulfosalicilic acid solution 200 mM were
added and incubated on ice for 10 min, in order to stop the reaction
and precipitate proteins. After incubation, samples are centrifuged
at 16,000 g at 4 C for 10 min. The supernatant is injected into the
HPLC system, and read at excitation 390 nm, emission 475 nm.
Acid-labile sulﬁde and bound sulfane sulfur. Acid-labile sulﬁde
consists of sulfur present in the iron-sulfur clusters contained in
iron-sulfur proteins (nonheme), while bound sulfane sulfur con-
sists of H2S bound to proteins (persulﬁdes, polysulﬁdes, etc). We
attempted to circumvent the problem linked to possible H2S
dispersion and preferred to omit needle removal of the solution by
utilizing one-pot extraction. 50 mL of plasma were placed into a
4 mL Vacutainer without additives, and mixed with 450 mL of
phosphate buffer 100mM, pH 2.6, 0.1 mMDTPA to release H2S from
the acid-labile pool. Another 50 mL of plasmawere then put in 4 mL
Vacutainer without additives, and mixed with 450 mL di phosphate
buffer 100 mM, pH 2.6, 0.1 mM DTPA, 1 mM tris(2-carboxyethyl)
phosphine (TCEP), in order to release bound sulfane sulfur. Samples
were then incubated for 30 min at room temperature on a rotating
shaker. After incubation, 500 ml of reaction buffer (Tris-HCl
300 mM, pH 9.5, 0.1 mM DTPA) were added, and incubated again
for 30 min, to trap the released H2S from acid-labile and sulfane
sulfur pools, and reach a conversion to HS which can then react
with MBB to form sulﬁde dibimane, SDB. 50 mL of sulfosalicilic
200 mM solution were added to stop the reaction and precipitate
proteins, and the mixture was incubated on ice for 10 min, then
centrifuged at 16000  g at 4 C for 10 min. The supernatant was
used for HPLC separation and ﬂuorescence detection. H2S concen-
tration was calculated utilizing a standard curve obtained with
Na2S standard solutions.
2.3. H2S detection with methylene blue method
(spectrophotometric)
Plasma was drawn utilizing EDTA Vacutainers (BD Diagnostics
368856, Italy). Samples were mixed with Zinc Acetate (to trap H2S),
N,N-dimethyl-p-phenylenediamine (40 mM in HCl 7.2 M) and FeCl3
(30 mM in HCl 1.2 M) [12]. To deproteinize samples, 10% trichlor-
acetic acid solution (TCA) was added. The ﬁnal product thus ob-
tained (methylene blue) was read spectrophotometrically at
670 nm (Thermo SpectronicBiomate 3 UV/VIS Spectrophotometer).
H2S concentration of plasma samples was calculated against a
standard curve obtained with NaHS.
2.4. H2S detection with potentiometric method (ion-selective
electrode)
Plasma was drawn utilizing lithium-heparin Vacutainers (BD
Diagnostics 368884, Italy). Each sample was mixed with an anti-
oxidant buffer (0.8 M sodium salicylate, 1.1 M NaOH, 0.2 M ascor-
bate) in 1: 1 ratio and in the dark for 20 min at room temperature.
After incubation, the potential was measured with a micro-
electrode (Lazar Research Inc., Los Angeles CA, USA) and
expressed in millivolts. The potential corresponds to the S2 ionconcentration, released under alkaline conditions from all H2S
present in the sample.
2.5. Plasma cysteine
Plasma from EDTA Vacutainers (BD Diagnostics 368856, Italy)
was used. 10% tris-butylphosphine (TBF) in dimethyl-formamide
(DMF) solution and 10% trichloracetic acid solution in EDTA 1 mM
were added to 300 mL of each sample and incubated at 4 C for
30 min. After incubation, samples were centrifuged and the su-
pernatant ﬁltered and mixed with 20 mL of 1.55 M NaOH solution
and 250 mL of 0.125 M borate buffer in 4 mM EDTA, and ﬁnally
derivatized with 100 mL of 7-ﬂuorobenzan-4-sulfonic acid (SBDF).
This mix was incubated at 60 C for 1 h 50 mL of derivatized samples
were analyzed by HPLC with ﬂuorescence detection. An XTerra
18RP (5 mm, 80Å, 4.6 250mm) columnwas usedwith an isocratic
ﬂow of 0.600 mL/min, mobile phase was KH2PO4 0.1 M, pH 2.1,
CH3CN 4%, ﬂuorescence detection (excitation 385 nm, emission
515 nm).
2.6. Plasma Hcy
Plasma from Citrate Vacutainer (BD Diagnostics 367704) was
used. Total Hcy from plasma samples was measured with an
automated latex enhanced immunoassay on IL Coagulation System
(HemosIL, Instrumentation Laboratory SpA, Milano, Italy).
2.7. Lanthionine, homolanthionine, free Hcy, homoserine,
cystathionine liquid chromatography tandem mass spectrometry
(LC-MS/MS) measurements
Hcy, homoserine, lanthionine, and cystathionine were pur-
chased from Sigma-Aldrich. All solutions and solvents were of the
highest available purity and were suitable for LCeMS analysis. All
stock solutions were stored at 20 C.
Serum from Vacutainer SST II Advance (BD Diagnostics 367955,
silica clotact/gel) of uremic patients and healthy volunteers was
used. Samples (200 mL) were subject to simple protein precipitation
with 600 ml ethanol and vortexed thoroughly. The mixture was
stored ate 20 C for about 30min to complete protein precipitation
and then centrifuged at 13,000 g for 10 min. Protein precipitation
with ethanol (1:3 v/v) at e 20 C for about 30 min resulted in the
highest yields for protein pellet and for all analytes. Extending the
precipitation time beyond 30 min (i.e., up to 2 h) did not increase
recovery. Moreover, this procedurewas compatible with themobile
phase for further LC; thus, this solvent was subsequently used
throughout the study. The supernatant was then directly trans-
ferred into HPLC auto sampler and 1 ml of supernatant was analyzed
in a LC-MS/MS assay. The LCeMS/MS analyses were carried out by
using a 6420 triple Q system with a HPLC 1100 series binary pump
(Agilent, Waldbronn, Germany). The analytical column was a Phe-
nomenex Kinetex 5u 100 A C18. Themobile phasewas generated by
mixing eluent A (2% acetonitrile, 0.1% formic acid) and eluent B
(95% acetonitrile and 0.1% formic acid), ﬂow rate 0.200 mL/min.
Starting condition was 5%e95% eluent A in 8 min, then brought to
100% in 2 min. Tandem mass spectrometry was performed using a
turbo ion spray source operated in positive mode, and the multiple
reaction monitoring (MRM) mode was used for the selected ana-
lytes. A standard solution of 500 pg\uL of each metabolite was used
for optimization of the MRM transitions (Fig. 1, panel A). The ideal
conditions for detection were determined via Agilent MassHunter
Optimizer software. Fig. 2 panel B shows the MRM chromatograms
obtained for each target analyte showing a good selectivity for all
analytes, with all transitions correctly occurring at the same
retention time. Standard calibration curves were constructed by
Fig. 2. Multiple reaction monitoring (MRM) analysis: Panel A. MRM mass spectral parameters. Panel B. MRM chromatogram of the target compounds. Transitions and corre-
sponding names are reported.
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tions were applied to the calibration curves. Data were integrated
by Mass Hunter quantitative software showing a linear trend in the
calibration range for all molecules. The coefﬁcients of determina-
tion (R2) were greater than 0.99 for all analytes. This method allows
for the simultaneous measurement of serum free lanthionine,
homolanthionine, free Hcy, homoserine, and cystathionine.
2.8. Cell cultures and reagents
The HepG2 cell line was purchased from American Type Culture
Collection (ATCC), Manassas, VA, USA. The cell line was grown in
Dulbecco's modiﬁed Eagle's medium (GIBCO® DMEM, Invitrogen™,
Carlsbad, CA) with 10% fetal bovine serum (FBS, GIBCO®) and 1%
non-essential amino acids (Lonza BioWhittaker®). The cell culture
medium was supplemented with 100 U of penicillin/ml, 100 mg of
streptomycin/ml, and 2 mM L-glutamine. Cells were grown at 37 C
in a humidiﬁed atmosphere with 5% CO2.
A modiﬁed methylene blue method assay was utilized, termed
“agar trap method”, allowing accurate H2S measurement in cellcultures without any H2S loss [13]. The method utilizes a modiﬁed
agar layer placed on the non-adherent surface of a cell ﬂask (1%
agar, 45 mM Zinc Acetate, 3 M NaOH). After solidiﬁcation of the
agar layer, cells were seeded and incubated overnight, then incu-
bated with different H2S-releasing compounds: L-cysteine (10 mM;
Sigma 30089-100G), DL-Hcy (10mM; Sigma H4628-1G), vitamin B6
(6 mM; Benexol, Bayer), AdoMet (1 mM; BioLabs B9003S), DL-
lanthionine (0.3 mM, the same concentration found in uremic
serum; Sigma L8543). Parallel samples were treated with DL-
Propargylglycine (PAG) 1 mM, a known CSE inhibitor, (Sigma
P7888-250MG) as a negative control. H2S, produced during 6 h and
24 h of incubation, was thus trapped in the agar layer, then released
and quantiﬁed in situ by adding to each ﬂask N,N-dimethyl-p-
phenylenediamine sulfate (Sigma 186384; 40mM in 7.2 MHCl) and
FeCl3 (Sigma 157740; 30 mM in 1.2 M HCl). After 20 min of incu-
bation, the absorbance was read at 670 nmwith Thermo Spectronic
Biomate 3 UV/VIS Spectrophotometer. The concentration was
calculated against a standard curve obtained with a NaHS solution
(Sigma 161527) as H2S donor, attained under the above-mentioned
conditions. The cell monolayer was monitored during the
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or detached due to unfavorable growth conditions. Further, cell
viability was checked by PrestoBlue viability assay [14] to assess
compound cytotoxicity.
2.9. Statistical analysis
Unpaired, paired, and one-sample Student's t-test was utilized
to compare means, as appropriate. Correlation tests (Pearson and
Spearman) were used to assess linear associations between two
variables. ONE-way ANOVA test for repeated measures was used in
the dialysis time-course experiments. The results were analyzed
with the statistics software GraphPad Prism Version 6.0a for
Macintosh (GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Opposite behavior of circulating levels of H2S and relevant
blood sulfur metabolites in uremic patients compared to those
measured in healthy subjects
In Table 1, the main biochemistries of patients selected for this
study are shown. These values are typical of those commonly
present in uremic patients on hemodialysis.
Plasma H2S levels measured with the monobromobimane HPLC
method were signiﬁcantly decreased in uremic patients with
respect to healthy controls (Fig. 3). In particular, while free H2S
levels were not signiﬁcantly different compared to controls (panel
A), bound sulfane sulfur (consisting of H2S bound to proteins, such
as persulﬁdes, polysulﬁdes, etc.), acid-labile sulﬁde (consisting of
sulfur present in the iron-sulfur clusters contained in nonheme
iron-sulfur proteins), and total H2S (panel B, C, D) were signiﬁ-
cantly reduced in uremic patients. Results, obtained with the
potentiometric and spectrophotometric method, conﬁrm that
plasma H2S levels were signiﬁcantly decreased in uremic patients
(panel E, F).
Results clearly showed that HPLC, as expected, allowed to
distinguish among different H2S fractions, while the other two
methods were not selective with respect to the various H2S pools.
In addition, it is clear that the three methods obtained different
absolute plasma H2S values. In particular, HPLC provided much
lower concentrations, compared with the other two methods.
However, all methods concur in demonstrating lower levels in
uremic patients, compared to control.
Conversely, circulating levels of the relevant sulfur metabolites
were signiﬁcantly elevated in uremic patients with respect to
control subjects (Table 2), with the exception of homoserine, which
was signiﬁcantly decreased in uremic patients. Particularly para-
doxical appeared the behavior of lanthionine and homolanthionine,Table 1
Main biochemical parameters (in parentheses units and normal laboratory values) of
uremic patients (mean ± standard error of mean, SEM).
Patients
Creatinine (mg/dL) (0.5e1.1) 8.56 ± 0.3
Urea (mg/dL) (12e50) 124.1 ± 5.6
Calcium (mg/dL) (8.6e10.5) 9.03 ± 0.1
Phosphorus (mg/dL) (2.4e4.1) 4.75 ± 0.2
Parathyroid hormone (pg/mL) (12e72) 320.8 ± 58.96
C Reactive Protein (mg/L) (<5) 7.08 ± 2.3
Albumin (g/dL) (3.5e5.2) 3.86 ± 0.10
Mean Corpuscolar Volume (fL) (85e98) 95.36 ± 1.6
Hemoglobin (g/dL) (13.5e17) 11.58 ± 0.2
Potassium (mmol/L) (3.6e5.0) 5.5 ± 0.09
Alkaline Phosphatase (U/L) (30e120) 85.6 ± 5.10which have been so far considered stable markers of H2S produc-
tion. In fact, and somewhat surprisingly, lanthionine levels were
increased by at least two orders of magnitude, in the patients
compared to control, while homolanthionine levels doubled, in the
face of generally decreased H2S pools.
Correlations between plasma H2S levels and homolanthionine
and lanthionine in uremic patients were also assessed. In uremic
patients, there were no signiﬁcant correlations between lanthio-
nine and plasma H2S levels considering all its measured forms.
However, there was a signiﬁcant positive correlation between
homolanthionine and total H2S and acid-labile sulﬁde (respectively,
r ¼ 0.3673, p < 0.01; and r ¼ 0.2977, p < 0.05), but not between
homolanthionine and bound sulfane sulfur and free H2S.
3.2. Basal plasma H2S pools differ in patients treated with various
types of dialysis
Data were stratiﬁed according to the type of dialysis: hemodi-
alysis (HD) low-ﬂux polysulfone, HD low-ﬂux polyethersulfone,
hemodiaﬁltration (HDF) high-ﬂux polysulfone, paired hemodiaﬁl-
tration (PHF) high-ﬂux polyethersulfone. Results are shown in
Table 3.
The free form was signiﬁcantly higher in the polysulphone-
treated patients, while it was lower with polyethersulphone. The
bound sulfane sulfur was lower in PHF patients, and higher in HDF.
The acid-labile form did not differ. Total levels measured with HPLC
were higher in HD and HDF and lower in PHF patients. These dif-
ferences are somewhat mirrored by the levels obtained with the
ion-selective electrode method, although the latter provided much
higher concentration values, as noted above. Conversely, with the
methylene blue method, levels were higher in patients treated with
polyethersulphone.
3.3. Plasma H2S and sulfur metabolites circulating concentrations
before and after a single dialysis session
For this study, results obtained in HD low-ﬂux polyethersulfone
and PHF high-ﬂux polyethersulfone dialysis patients were merged.
Free H2S didn't change after a single dialysis session, bound sulfane
sulfur increased but not signiﬁcantly, while acid-labile sulﬁde and
total H2S decreased signiﬁcantly after dialysis. Plasma H2S levels
measured with the potentiometric method increased signiﬁcantly
after dialysis; however, H2S measured with the spectrophotometric
method (methylene blue method) didn't show signiﬁcant differ-
ences after dialysis (Table 4).
Sulfur metabolites levels decreased signiﬁcantly after dialysis,
with the exception of free Hcy, which was not different, and
homoserine and homolanthionine, which decreased, but not
signiﬁcantly (Table 5).
Then the two patient groups (HD low-ﬂux polyethersulfone and
PHF high-ﬂux polyethersulfone) were considered separately,
observing the following.
Free H2S increased signiﬁcantly after PHF, but not after HD
(Fig. 4, panel A). Bound sulfane sulfur increased signiﬁcantly after
PHF, but not after HD (panel B); levels were signiﬁcantly lower in
PHF at the start of dialysis with respect to HD. Acid-labile sulﬁde
decreased signiﬁcantly after HD, but not after PHF (panel C). Total
H2S decreased signiﬁcantly after HD, but not after PHF (panel D).
H2S measured with the potentiometric method increased signiﬁ-
cantly after HD dialysis and increased, but not signiﬁcantly, after
PHF dialysis (panel E), while H2S measured with spectrophoto-
metric method didn't shown any signiﬁcant variations after HD and
PHF dialysis (panel F).
Both types of dialysis were able to signiﬁcantly remove the
sulfur metabolites of interest (Fig. 5), although to different
Fig. 3. H2S measured in its various forms with the MBB method (HPLC, panels A-D), potentiometric method (ion-selective electrode, panel E), spectrophotometric method
(methylene blue method, panel F), (mean ± SEM). Controls (white bar); patients (black bar). *p < 0.05, **p  0.01, ***p < 0.001.
Table 2
Values of the various relevant sulfur metabolites (mean ± SEM).
Controls Patients
Hcy (mM) 13.50 ± 2.6 35.95 ± 2.5***
Cys (mM) 76.44 ± 2.7 145.3 ± 7.1***
Free Hcy (mM) 0.68 ± 0.08 1.29 ± 0.09***
Cystathionine (mM) <0.002a 5.42 ± 0.5***
Homoserine (mM) 6.13 ± 0.2 5.53 ± 0.3*
Lanthionine (mM) <0.002a 0.32 ± 0.03***
Homolanthionine (mM) 0.26 ± 0.04 0.52 ± 0.1*
*p < 0.05,***p < 0.001.
a Detection limit.
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It can also be noted that basal levels (the pre-dialysis values) ofsulfur metabolites in PHF were lower than those present in HD
(Fig. 5).
Plasma H2S levels during a single dialysis session (time course)
were measured (Fig. 6). Results showed that bound sulfane sulfur
levels increase signiﬁcantly during PHF (panel D), but not in HD
(panel C), while acid-labile sulﬁde decreased signiﬁcantly during
HD (panel E), but not in PHF (panel F). Interestingly, variations
started from the initial stages of the dialysis session and changed
gradually. Total and free H2S, in both types of dialysis, did not vary
signiﬁcantly (panel A, B, G, H).
H2S measured with potentiometric method did not show any
signiﬁcant variation during HD and PHF dialysis; also H2Smeasured
with spectrophotometric method did not shown any signiﬁcant
variation during HD and PHF dialysis (not shown).
Table 3
Values of H2S with the three different methods (mean ± SEM).








Monobromobimane method, HPLC (Free) 8.16 ± 0.2a*** 4.04 ± 0.4 8.23 ± 0.6 3.40 ± 0.5b***
Monobromobimane method, HPLC (boundsulfane
sulfur)
2.03 ± 0.2 2.1 ± 0.3 3.02 ± 0.6c* 1.36 ± 0.3
Monobromobimane method, HPLC (Acid-labile sulﬁde) 4.11 ± 0.4 5.57 ± 0.4 4.50 ± 0.9 5.82 ± 0.6
Monobromobimane method, HPLC (Total) 14.06 ± 0.5a* 11.85 ± 0.7 16.10 ± 1.5b* 10.60 ± 0.9
Ion-selective electrode 75.32 ± 2.1a** 58.68 ± 8.6 74.39 ± 2.8 53.87 ± 8.1b**
Methylene blue method 26.93 ± 3.8 36.63 ± 4.6 24.53 ± 3.6 38.53 ± 2.5b*
*p < 0.05, **p  0.01, ***p < 0.001.
a HD polysulfonevs HD polyethersulfone.
b HDF polysulfonevs PHF polyethersulfone.
c HD polysulfonevs HDF polysulfone.
Table 4
H2S measured in its various forms with the MBB method (HPLC), potentiometric method (ion-selective electrode), and spectrophotometric
method (methylene blue method) before (PRE) and after dialysis (POST) (mean ± SEM).
H2S (mM) PRE POST
Monobromobimane method, HPLC (Free) 3.83 ± 0.3 3.80 ± 0.3
Monobromobimane method, HPLC (boundsulfane sulfur) 1.49 ± 0.2 1.57 ± 0.2
Monobromobimane method, HPLC (Acid-labile sulﬁde) 5.74 ± 0.3 4.44 ± 0.3***
Monobromobimane method, HPLC (Total) 11.45 ± 0.6 9.6 ± 0.5**
Ion-selective electrode 73.21 ± 9.9 79.86 ± 10.6**
Methylene blue method 34.16 ± 3.5 29.75 ± 3.9
*p < 0.05,**p  0.01,***p < 0.001.
Table 5
Relevant sulfur metabolites levels before (PRE) and after dialysis (POST),
(mean ± SEM).
PRE POST
Hcy (mM) 39.98 ± 6.78 26.48 ± 5.6***
Cys (mM) 139.2 ± 13.73 64.31 ± 6.8***
Free Hcy (mM) 1.59 ± 0.4 1.44 ± 0.3
Cystathionine (mM) 6.83 ± 1.6 1.59 ± 0.5**
Homoserine (mM) 5.45 ± 0.8 4.03 ± 0.3
Lanthionine (mM) 0.34 ± 0.06 0.15 ± 0.03**
Homolanthionine (mM) 0.22 ± 0.03 0.13 ± 0.05
**p  0.01, ***p < 0.001.
A.F. Perna et al. / Biochimie 126 (2016) 97e107 1033.4. Lanthionine inhibits H2S production by interfering with CBS
activity
Among the various sulfur metabolites altered in uremic patients
on hemodialysis, we focused particularly on lanthionine, since this
compound had been shown to speciﬁcally inhibit CBS [15],
although no data is available about the possible effects of this
interference on H2S production. Hepatocarcinoma cell line (HepG2)
expresses all the enzymatic machinery for sulfur amino acid
metabolism including the transsulfuration pathway. Therefore,
HepG2 appear to be one of the most appropriate cell systems to
study H2S production, and the regulatory properties of the major
enzymes involved, CBS and CSE. HepG2 cells were incubated with
various substrates and cofactors for H2S production (Hcy, Cys, S-
adenosylmethionine, etc.) with or without lanthionine, at concen-
trations comparable to those measured in the uremic serum in this
study, utilizing the agar trap assay system.
Results in Fig. 7 show the amount of H2S produced by HepG2
cells during 6 h (panel A), and 24 h (panel B), upon lanthionine
treatment and in the presence of the indicated substrates and
cofactors.
The total amount of H2S produced after 24 h of incubation was
generally higher than that produced after 6 h (panel B vs panel A).
H2S release in cells incubated with Hcy, Cys, S-adenosylmethionine(AdoMet) and vitamin B6 was signiﬁcantly higher compared to
control cells. This increase was signiﬁcant at 6 h and could still be
detected after 24 h of incubation (compare panel A and B in Fig. 6).
Pre-treatment with lanthionine decreased signiﬁcantly the amount
of H2S produced by cells during 6 h incubation under conditions of
maximal H2S release (Fig. 7, panel A). This effect was still signiﬁ-
cant, although less pronounced, after 24 h of incubation (Fig. 7,
panel B). The extent of lanthionine inhibition of H2S release was
comparable to the effect of DL-propargylglycine (DL-PAG), a known
transsulfuration inhibitor, observed at both 6 and 24 h incubation
times (Fig. 7). Importantly, the inhibitory effect of lanthionine on
H2S release was nearly abolished when samples were incubated in
the absence of AdoMet, both at 6 and 24 h (Fig. 7).
These results demonstrated that increased lanthionine, as the
result of CKD, can effectively reduce H2S production in the liver,
thus establishing an altered metabolic crosstalk between these two
organs.
4. Discussion
CKD patients, including those undergoing maintenance dialysis,
have a disproportionately high morbidity and mortality due to CV
disease. Traditional risk factors and those linked to the severe loss
of kidney function cannot entirely explain this CV risk increase [16].
H2S is involved in modulation of various physiological re-
sponses. In general, it acts as a protective agent in oxidation,
inﬂammation, and apoptosis, all events paving theway to acute and
chronic diseases such as ischemia-reperfusion injury, pulmonary
hypertension, atherosclerosis, and notably CKD progression and
complications [1,17].
Plasma H2S levels, measured spectrophotometrically, are
reduced in hemodialysis patients with respect to healthy controls
[2,18]. This reduction was attributed to the down-regulation of CSE
expression [2]. Aminzadeh and Vaziri also demonstrated low H2S
levels in a rat model of CKD; the alteration is linked to CKD pro-
gression [3].
The best method for H2S measurement has caused considerable
Fig. 4. H2S measured in its various forms with the MBB method (HPLC), potentiometric method (ion-selective electrode), spectrophotometric method (methylene blue method),
before (PRE) and after dialysis (POST) in HD polyethersulfone and PHF (mean ± SEM). PRE HD (white bar), POST HD (vertical line bar), PRE PHF (black bar), POST PHF (cross-hatched
bar). *p < 0.05, **p  0.01, ***p < 0.001.
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sulphide anion, HS¡), acid-labile (bound to the sulfur-iron clusters
of proteins), bound sulfane sulfur (bound to proteins, i.e. poly-
sulﬁdes, persulﬁdes, etc.) [10,19]. Total H2S refers to all these forms
together. Total H2S levels can be measured with different methods,
as mentioned, among which the most commonly used is the
methylene blue method with spectrophotometric detection.
However, this method allows to quantify free H2S, although, due to
acidic sample treatment, acid-labile sulﬁde can be also freed to
some extent, thus possibly and unpredictably decreasing overall
accuracy. The potentiometric method, utilizing a micro-electrode,
measures the S2 ion directly. It actually allows to quantify the
free form, plus the bound sulfane sulfur, by mixing the sample with
an antioxidant buffer (a strong alkaline solution). Consequently,
results provided this method may be inaccurate, and/or difﬁcult to
interpret. The most selective and accurate method is given by HPLC
separation and detection, because the sample is derivatized withmonobromobimane, and, by using a hypoxic chamber, there is no
H2S dispersion. In addition, all H2S forms can be measured sepa-
rately. In this article, all threemethods were utilized and compared.
In our work, plasma H2S levels are decreased in uremic patients
with respect to healthy controls, only partly in line with previous
results. In fact, this reduction is conﬁned to the acid-labile sulﬁde,
bound sulfane sulfur forms, and total levels, as evidenced by results
obtained with the HPLC method, while free levels did not vary
signiﬁcantly.
Key enzymes in H2S production are CBS and CSE. These enzymes
utilize as substrates Cys and Hcy, whose levels are both increased in
uremic patients. Two of the various H2S generating reactions, i.e.Cys
b-replacement and Hcy g-replacement, yield lanthionine or
homolanthionine [8], two novel sulfur metabolites, which have
been proposed to be useful for monitoring H2S production.
Our results show that, like all the other sulfur metabolites,
lanthionine and homolanthionine are increased in uremic patients
Fig. 5. Concentrations of the various sulfur metabolites, before (PRE) and after dialysis (POST) in HD polyethersulfone and PHF (mean ± SEM). PRE HD (white bar), POST HD (vertical
line bar), PRE PHF (black bar), POST PHF (cross-hatched bar). *p < 0.05, **p  0.01.
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opposite modiﬁcations in H2S concentrations. A major difference is
seen regarding lanthionine, which increases by about two orders of
magnitude, while homolanthionine doubles.
Lanthionine is involved in CBS inhibition [15], and our resultsshowed that this inhibition determines a signiﬁcant impairment of
H2S production in cell cultures. Then, as well, it can be hypothe-
sized that the increase in blood levels of this compound found in
our patients could contribute at least in part to the degree of
hyperhomocysteinemia in uremia, thus providing a mechanism in
Fig. 6. Time course of the various forms of H2S, in a single dialysis session, in HD polyethersulfone and PHF (mean & whiskers min to max).*p < 0.05 **p  0.01.
Fig. 7. Amount of H2S produced by HepG2 cells incubated with various substrates. Panel A) 6 h of incubation; panel B) 24 h of incubation (mean ± SEM). *p < 0.05, **p  0.01,
***p < 0.001. White bar ¼ Control. Black bar ¼ DL-Hcy 10 mM þ L-Cys 10 mM þ AdoMet 1 mM þ vitamin B6 6 mM. Horizontal line bar ¼ Pre-incubation of 2 h with DL-lanthionine
0.3 mM and incubation with DL-Hcy 10 mM þ L-Cys 10 mM þ AdoMet 1 mM þ vitamin B6 6 mM. Checkered bar ¼ DL-Hcy 10 mM þ L-Cys 10 mM þ vitamin B6 6 mM. Vertical line
bar ¼ Pre-incubation of 2 h with DL-lanthionine 0.3 mM and incubation with DL-Hcy 10 mM þ L-Cys 10 mM þ vitamin B6 6 mM. Cross-hatched bar ¼ Pre-incubation of 2 h with DL-
PAG 1 mM and incubation with DL-Hcy 10 mM þ L-Cys 10 mM þ AdoMet 1 mM þ vitamin B6 6 mM.
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completely understood. It has been in fact suggested that hyper-
homocysteinemia in uremia may be due to inhibition, by an un-
known uremic toxin, of Hcy-metabolizing enzymes, which is
supported by the ﬁnding of reduced CSE transcription in mono-
nuclear cells in vivo in uremic patients [2].
Our present data showed rather high circulating levels of the
amino acid homoserine in the normal; these levels are decreased in
uremia and are further lowered by dialysis, indicating that this is
not a substantial retention product. Homoserine has been proposed
as an alternative major product of H2S formation fromHcy, by a, g -
elimination reaction carried out by CSE [8]. Therefore, we can
suggest that homoserine is a more likely indicator of reduced H2S
production in uremia, compared to homolanthione and
lanthionine.
The type of dialysis inﬂuences the levels of the different forms of
H2S. Comparing the four different types of dialysis (low-ﬂux HD
with polysulfone and polyetersulfone, and high-ﬂux HDF with
polysulfone and PHF with polyetersulfone), it emerges that the
bound form and accordingly the total H2S levels are increased in
high-ﬂux dialysis with polysulfone. The other methods give
somewhat different results, perhaps mirroring the different moi-
eties to which the speciﬁc method is sensitive. Considering the
effects of a single session, the acid labile form is dialyzed, while the
bound forms tends toward an increase, as also indicated by the
signiﬁcant increase seen with the ion selective method. If the two
types of dialysis are analyzed separately, in PHF, the bound form
increases, although the patients start with lower levels, and all
sulfur compounds taken as a whole are dialyzed better, while with
HD with polyethersulfone all H2S forms are removed, as well as the
sulfur compounds of interest.
We previously reported on the ability of a single hemodialysis
session to increase plasma H2S [17]. However, these patients were
notwell characterizedwith respect to B vitamin status, in particular
folate levels, or type of dialysis or ﬁlter utilized, or other dialysis
parameters, such as dialysis time, vintage, Kt/V, etc. In the present
study, only PHF patients showed a non-signiﬁcant increase in total
levels, and a signiﬁcant increase in bound sulfane sulfur.
Homolanthionine and especially lanthionine are removed
rather efﬁciently by dialysis, in that their levels are reduced by half
(better with PHF), although far from being normalized, particularly
in the case of lanthionine. In the time-course experiments, PHF
treatment induces an increase in the bound sulfane sulfur form,
which is perhaps a remarkable feature, in consideration of the
functional meaning of this H2S pool. Changes occur during the
whole dialysis session, without any abrupt modiﬁcation, that is
they start from the beginning of treatment, suggesting that these
variations are due to dialysis and not to other dialysis-related fac-
tors (e.g. hypotension at the end of dialysis session). All in all, the
high-ﬂux techniques seem to perform better compared to low-ﬂux,
in terms of respecting the bound H2S form concentration, and in
terms of lanthionine removal.
5. Conclusions
This work underlines the value of measuring H2S in its various
forms, because it emerged that, in uremia, prevalently it is the
bound form which is affected. The sulfur compound lanthionine,
far from being a marker of H2S production, emerges as novel
uremic retention product, recommending cautious assessment of
parameters of renal function before assuming that lanthionine or
homolanthionine levels may adequately monitor H2S production
in vivo. Lanthionine accumulation is able to hamper H2S produc-
tion and could contribute, at least in part, to the development ofhyperhomocysteinemia in uremia, therefore representing a new
uremic toxin.Disclosure
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